Annexon ANNX Accrued And Other Liabilities Current
Accrued And Other Liabilities Current at other companies
Other financials
Where this comes from
Reported directly by Annexon in its filing.
Tagged under the XBRL concept annx:AccruedAndOtherLiabilitiesCurrent.
The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Annexon's accrued and other liabilities current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Annexon's accrued and other liabilities current?
- Annexon (ANNX) reported accrued and other liabilities current of $15.39M in Q1 2026.
- How has Annexon's accrued and other liabilities current changed year-over-year?
- Annexon's accrued and other liabilities current decreased by 24.9% year-over-year, from $20.49M to $15.39M.
- What is the long-term trend for Annexon's accrued and other liabilities current?
- Over 2 years (2023 to 2025), Annexon's accrued and other liabilities current has grown at a 55.3% compound annual growth rate (CAGR), from $10.28M to $24.79M.
- What does accrued and other liabilities current mean?
- This metric represents the aggregate of short-term obligations that are not classified as accounts payable or debt, including items such as accrued compensation, professional fees, and other operational expenses expected to be settled within one year. For a clinical-stage biopharmaceutical company, this balance often reflects the timing of research and development activities and clinical trial costs that have been incurred but not yet invoiced or paid. Monitoring this figure helps investors assess the company's near-term cash outflow requirements and the efficiency of its working capital management.